RasbInNL
Posted - 1 day ago
@Weedman99 I feel that about $MBIO ...that one really kills me. They're literally trying to save lives and yet people still short...
Svitlana
Posted - 2 days ago
$MBIO
Nibble It can go lower, but it does run volatile too 👀
DBL_07
Posted - 2 days ago
$MBIO looks prime to run
RasbInNL
Posted - 2 days ago
$MBIO Any idea of when news about the other trials could come. It's got promising data. https://rarecancernews.com/news/virus-based-mb-108-named-fda-orphan-drug-malignant-glioma/
flyinghollaender
Posted - 3 days ago
$FBIO $DERM $CKPT $MBIO $ATXI
Zellchair
Posted - 3 days ago
$FBIO Are these updates enough since they initiated the PT $24 analysis for the first time? FBIO - New favorable loan deal with Oaktree - FBIO holdings in several core subsidaries increased last quarter - More insider buying $DERM - Emrosi FDA approval $CKPT - Cosibelimab BLA approved - Positive update on Cosibelimab long-term results in cSCC at ESMO - CKPT temporarily stable economic situation given the warrants $MBIO - MB-106 fantastic P1/2 results in WM . MB-108 Granted Orphan Drug Designation $ATXI - AJ201 1b/2 study completed From unlisted subsidaries - Confirmation of CUTX-101 NDA application - Extended studies for CAEL-101 - CAEL-101 P3a/b starts - Urica's deal with Crystalys regarding Dotinurad - Triplex P2 start in Liver transplantation Milestones drawn from the head quickly, must have missed a lot.
Zellchair
Posted - 3 days ago
$FBIO $CKPT $MBIO Strategy - Part 2/2 Can reason about the same with MB-106, due to its data and a possible more uncertain future of MB-109 given the combination of MB-101 and MB-108. Potential milestones/royalties for Cosibelimab, CUTX-101 and CAEL-101 could then be close at the same time as we now know that MB-106 is pivotal study ready and that Dotinurad can soon get the go-ahead for its two (Gout and Hyperuricemia respectively) P3. These then given the lines in part 1 in a model where the money inflow can only come one way via income and no more costs. Then FBIO can prioritize maintaining ownership in Cyprium depending on how to think about the future of AAV-ATP7A Gene Therapy (CUTX-101 2.0), Urica depending on the arrangement with Crystalys but also $DERM and Helocyte.
Zellchair
Posted - 3 days ago
$FBIO Strategy - Part 1/2 It is difficult to open the faucet when it has been turned off for some time. Especially in expensive overheads in oncology and CAR-T. Therefore, I see a likely scenario that selling $MBIO mainly but also $CKPT is the main track for FBIO in the next few months. Take 5% of each off the table in a cash, end the remaining ownership and the right to the 2.5% annual equity dividend (think many underestimate the value of this) to increase the 4.5% royalty, and maybe even milestones for the drug's development in early stages such as start of pivotal study, completed study, NDA application accepted, FDA approval, etc. Try to make a deal where the percentage of royalties is weighted towards mainly Cosibelimab (also Olafertinib if you feel confident about the asset's future) partly because of where it is in the process but also the combination possibilities in the future (see previous post).
Radcon2017
Posted - 4 days ago
$MBIO That is not a lot of time to right the good ship MBIO…possibly a Reverse Split followed by a financing? Jan 31 & Feb 18 is not a lot of time. From the news release…
“the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement through January 31, 2025 and the $2.5 million stockholders’ equity requirement through February 18, 2025. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.”
First_Class_Seaman
Posted - 5 days ago
$MBIO it ran from this level last time with news. Ill load sum here.
$ZCAR recently RS. WW.
$ZONE bottom chart and been holding very well at 2.
Heretomakemoney_
Posted - 6 days ago
$XTIA 💥💥 $IVP $MBIO $ALLR
SMM82
Posted - 6 days ago
$MBIO Back to $0.13 level pretty quickly if $0.21 doesn’t hold.
Joey2235
Posted - 6 days ago
$MBIO For anyone that wants to track the progress of the most critical trial. https://clinicaltrials.gov/study/NCT03277729
The last update was in June…last time saw a significant surge in price over a $1.
Last update was 6/12
Sr2012
Posted - 6 days ago
$MBIO 13G filed just now, Armistace Capital LLC buys 4.99% of the total shares
QuantNut
Posted - 1 week ago
$MBIO back in.
ShipIttwice
Posted - 1 week ago
$MBIO 💩
eyeownu
Posted - 1 week ago
$MBIO whats hattnin. ready for another monster pump. where is my kitty
Zellchair
Posted - 1 week ago
$FBIO $TGTX $CKPT $MBIO Just to clarify, it was obviously Weiss who made that $31 M bet. Weiss and Rosenwald go back further than that. Weiss managed Paramount Capital/Aries Funds alongside Rosenwald who took him under his wing. When the disciple becomes the master.
Zellchair
Posted - 1 week ago
$FBIO $TGTX $CKPT $MBIO $31 M… Today years later, TG-1101 (ublituximab) is TG first and to date only approved product with the name BRIUMVI® (ublituximab-xiiy), and at the time of writing the stock is valued at over $5.44 B. 17451.61% on investment and a CAGR of 49.9%... And the craziest thing? BRIUMVI and TGTX are just in the starting block. FBIO Management can be trusted.
Zellchair
Posted - 1 week ago
$FBIO $TGTX $CKPT $MBIO In TG 2013 annual report, the financial details of the Ublituximab deal are revealed for the first time: "In January 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics, and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of TG-1101. Under the license agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of TG-1101 at a royalty rate that escalates from mid-single digits to high-single digits.” (P. 12, https://ir.tgtherapeutics.com/static-files/354aef57-52b3-4ea5-9bd6-6268c0d4ed19)
Zellchair
Posted - 1 week ago
$FBIO Executive Vice Chairman, Strategic Development Michael S. Weiss of FBIO and Chairman of $CKPT & $MBIO shares in his $TGTX are worth $460 M today. No one is probably prouder than FBIO Founder/President/CEO Lindsay Rosenwald.
amf99
Posted - 1 week ago
$MBIO they got a 90 day extension from being delisted. could we read into this that there is some good news coming ??
Joey2235
Posted - 1 week ago
$MBIO Stock Holder Equity as of 9/30 was (8,656) with 36M OS. During October the warrants exercised $4M and brought the OS to 47M as of the 11/4 per the 10Q. So brought in approx $2.3M in cash in October from the conversion with another $1.7M to go. Still need to find a way to increase the SHE by $6-7M by 2/15 to avoid delisting
CW630
Posted - 1 week ago
$MBIO they'll have to r/s then dilution before 2/18/25. Just keeping on backburner since 20c stocks are still hot for now.
Joey2235
Posted - 1 week ago
$MBIO “$2.5 million stockholders’ equity requirement through February 18, 2025”
Just a reverse split isn’t going to cure the earliest extension deadline. It will do the opposite most likely. Need to find some non dilutive financing OR hopefully release some MB106 trial results that will actually create stockholder equity….fingers crossed 🤞🏻
DARKP00L
Posted - 1 week ago
$MBIO ﹩0.27 - Mustang Bio Receives Positive Listing Determination from Nasdaq #pennystock #stockmarket #lowfloat #stockstotrade #stockscanner #tradinginsights #NYSE #darkpools
Zellchair
Posted - 1 week ago
$FBIO Part 2 Then I valued all of these companies at $0: Cellvation - $0 Oncogenuity - $0 Avenue $ATXI - $0 Mustang $MBIO - $0 Comments: Is this then reasonable? Of course not. The contrasts of the top two against the bottom are telling here. FBIO has a high ownership stake in the first two but has not prioritized these as the overall opportunities for the entire business have been better in the near term elsewhere. In MBIO and ATXI there is low ownership and thus low risk, but with longer and proven assets that have shown fantastic data so far. Aevitas - $0.35 M Estimated: 10% chance of FDA approval where 4D-175 only reaches 25% of milestones/royalties. Comments: Not close to reasonable here either when 4D-175 is a combined drug where FDMT have already confirmed data. If 4D-175 succeeds, then presumably only the FDA approval will secure close to 25% in milestone directly on the day, without sales. And if you're mad now, I haven't even started...
Radcon2017
Posted - 1 week ago
$MBIO $FBIO…Looking at the MBIO share price, cash remaining, and their NASDAQ listing Requirements, what are the options for $MBIO going forward?
1. Sell parts of their business to raise cash?
2. Sell the whole company to a large pharma that has the finances to complete the work MBIO is focused on?
3. Be acquired by FBIO?
4. Reverse Split followed by a Fresh Financing?
5. Merge with another Biotech that has the Financial strength to help reorganize their business and push the company forward?
6. MBIO delisted as they do not meet listing requirements?
7. Continue as they are hoping that their bullish results will set the stage for some bullish future event to happen that addresses market concerns?
I would expect news soon on what the future holds for MBIO…
All just my opinion, no guarantees here…
Joey2235
Posted - 1 week ago
$MBIO 10Q out- Quick snapshot
-46M shares outstanding -Approx 7.5M in cash (3.5 + 4 from ex warrants in Oct)
-had a hearing with the NASDAQ for an extension for delisting, no word back yet “The hearing took place on October 29, 2024, and we are currently awaiting the decision of the Panel”
-Orphan Drug status granted, however not enough $ to pursue a trial at this time, which explains the mediocre reaction Success or failure is all about MB106 trials https://www.sec.gov/ix?doc=/Archives/edgar/data/1680048/000155837024015048/tmb-20240930x10q.htm
